| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/16/2006 | EP1689739A1 Azole-based kinase inhibitors |
| 08/16/2006 | EP1689737A1 Beta-lactams for the treatment of cns disorders |
| 08/16/2006 | EP1689736A2 Biocidal siloxane coating material containing n-halogenated amine and amide functional groups |
| 08/16/2006 | EP1689732A2 Cationic substituted benzofurans as antimicrobial agents |
| 08/16/2006 | EP1689731A1 2-phenyl-benzofuran derivatives, method for the production thereof and their use |
| 08/16/2006 | EP1689730A1 Gsk-3 inhibitors isolated from marine organisms |
| 08/16/2006 | EP1689726A1 5-(benz- (z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents |
| 08/16/2006 | EP1689724A1 Quinazolinone compounds as anticancer agents |
| 08/16/2006 | EP1689723A1 Reference standard for characterization of rosuvastatin |
| 08/16/2006 | EP1689722A2 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders |
| 08/16/2006 | EP1689721A1 Aminopyrazole derivatives as gsk-3 inhibitors |
| 08/16/2006 | EP1689720A1 Pyrazolyl derivatives in the form of drugs for treating acute or chronic neuronal regressions |
| 08/16/2006 | EP1689719A1 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| 08/16/2006 | EP1689718A1 1-amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 activity |
| 08/16/2006 | EP1689717A1 Substituted isoquinolines useful in the treatment of diseases such as cancer and atherosclerosis |
| 08/16/2006 | EP1689716A1 Biaryl sulfonamides and methods for using same |
| 08/16/2006 | EP1689715A1 Tubulin inhibitors |
| 08/16/2006 | EP1689714A2 Therapeutic use of pyridinium compounds to modulate naadp activity |
| 08/16/2006 | EP1689713A1 Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer s disease |
| 08/16/2006 | EP1689712A1 4-phenylpiperidine derivatives as renin inhibitors |
| 08/16/2006 | EP1689711A1 Method for producing n- 1-(s)-carbalkoxy-3-phenylpropyl|-s-alanyl-2s, 3ar, 7as-octahydroindol-2-carboxylic acid compounds |
| 08/16/2006 | EP1689710A1 Indole derivatives for use as chemical uncoupler |
| 08/16/2006 | EP1689708A1 N-acyl-n -benzyl-alkylendiamino derivatives |
| 08/16/2006 | EP1689707A1 Novel compounds for the treatment of obesity |
| 08/16/2006 | EP1689706A2 Alpha, beta-unsaturated sulfoxides for treating proliferative disorders |
| 08/16/2006 | EP1689705A2 Fused ring dicationic anti-protozoan agents and their prodrugs |
| 08/16/2006 | EP1689704A2 Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents |
| 08/16/2006 | EP1689703A1 Resolution of 3-amino alkylnitriles |
| 08/16/2006 | EP1689702A1 Organic compounds |
| 08/16/2006 | EP1689700A1 Novel salicylic anilides |
| 08/16/2006 | EP1689699A2 Anthranilic acid derivatives and their use as activators of the hm74a receptor |
| 08/16/2006 | EP1689698A1 Bis-cationic compounds and use thereof |
| 08/16/2006 | EP1689493A1 Calcitonin gene related peptide receptor antagonists |
| 08/16/2006 | EP1689489A1 Peptidically buffered formulations for electrotransport applications and methods of making |
| 08/16/2006 | EP1689453A1 Silver coatings and methods of manufacture |
| 08/16/2006 | EP1689447A2 Gene transfer for regulating smooth muscle tone |
| 08/16/2006 | EP1689444A1 Dna delivery with gemini cationic surfactants |
| 08/16/2006 | EP1689439A2 Small molecule compositions and methods for increasing drug efficiency using compositions thereof |
| 08/16/2006 | EP1689431A1 Cytoprotective effects of ethyl pyruvate |
| 08/16/2006 | EP1689428A2 Minimization of drug oxidation in drug irradiated excipients formulations |
| 08/16/2006 | EP1689415A1 Agents for improving iron uptake |
| 08/16/2006 | EP1689414A1 Polynucleotides for reducing respiratory syncytial virus gene expression |
| 08/16/2006 | EP1689413A2 Glycerophospholipids containing omega-3 and omega-6 fatty acids |
| 08/16/2006 | EP1689412A2 Vitamin d analogs for obesity prevention and treatment |
| 08/16/2006 | EP1689411A2 Graduated estrogen contraceptive |
| 08/16/2006 | EP1689410A2 Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol |
| 08/16/2006 | EP1689409A1 Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| 08/16/2006 | EP1689408A1 Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines |
| 08/16/2006 | EP1689407A1 Method of treatment of atherosclerosis |
| 08/16/2006 | EP1689406A2 Heterocyclic inhibitors of mek and methods of use thereof |
| 08/16/2006 | EP1689405A1 Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance |
| 08/16/2006 | EP1689404A1 Combination |
| 08/16/2006 | EP1689403A2 Heteroaryl-hydrazone compounds |
| 08/16/2006 | EP1689402A1 Combination therapy comprising the use of et-743 and doxorubicin for treating cancer |
| 08/16/2006 | EP1689401A1 Method for reducing pain |
| 08/16/2006 | EP1689400A2 Novel compound, corresponding compositions, preparation and/or treatment methods |
| 08/16/2006 | EP1689399A1 A tetrahydroquinoline derivative for treating nicotine craving |
| 08/16/2006 | EP1689398A2 Compositions comprising organic compounds |
| 08/16/2006 | EP1689397A2 Amelioration of macular degeneration and other ophthalmic diseases |
| 08/16/2006 | EP1689396A1 Prevention and/or reduction of photoreceptor degeneration with retinoids |
| 08/16/2006 | EP1689395A2 Vinca derivatives |
| 08/16/2006 | EP1689394A1 Amino substituted pyridinyl methanone compounds useful in treating kinase disorders |
| 08/16/2006 | EP1689393A2 Preparation of 1,7-disubstituted azabenzimidazoles as kinase inhibitors |
| 08/16/2006 | EP1689392A1 N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| 08/16/2006 | EP1689391A2 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylinositol 3 kinase enzymes (pi3) for the treatment of inflammatory airway diseases |
| 08/16/2006 | EP1689390A2 Methods and reagents for the treatment of inflammatory disorders |
| 08/16/2006 | EP1689389A2 Indole compounds |
| 08/16/2006 | EP1689388A1 Association of antimicrobial compounds with surfaces and polymers |
| 08/16/2006 | EP1689387A2 Bicyclic inhibitors of mek and methods of use thereof |
| 08/16/2006 | EP1689386A1 Tubular proteinuria as an indicator for elevated cardiovascular risk |
| 08/16/2006 | EP1689385A2 Neuroactive substance and uses of one such substance |
| 08/16/2006 | EP1689384A1 Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity |
| 08/16/2006 | EP1689383A2 Novel phosphorus-containing thyromimetics |
| 08/16/2006 | EP1689382A1 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and an agent intervening in the prostaglandin metabolism |
| 08/16/2006 | EP1689381A1 Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases |
| 08/16/2006 | EP1689380A2 Method for treating adamts-5-associated disease |
| 08/16/2006 | EP1689379A2 Methods of treating cancer with hdac inhibitors |
| 08/16/2006 | EP1689378A1 Novel use of peptide compounds for treating central neuropathic pain |
| 08/16/2006 | EP1689372A1 Compositions for conjugated estrogens and associated methods |
| 08/16/2006 | EP1689371A2 Pharmaceutical compositions of mirtazapine |
| 08/16/2006 | EP1689370A2 Method for the production of a solid, orally applicable pharmaceutical composition |
| 08/16/2006 | EP1689368A1 Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
| 08/16/2006 | EP1689367A1 Pharmaceutical formulations containing quetiapine |
| 08/16/2006 | EP1689366A1 Macrogol preparation |
| 08/16/2006 | EP1689364A1 Stable liposome compositions comprising lipophilic amine containing pharmaceutical agents |
| 08/16/2006 | EP1689363A2 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
| 08/16/2006 | EP1689361A2 Therapeutic combinations and methods including irm compounds |
| 08/16/2006 | EP1689356A1 Topical compositions associating sodium hyaluronate fragments and retinoid |
| 08/16/2006 | EP1689355A1 Selective inhibitors of nuclear factor-kb activation and uses thereof |
| 08/16/2006 | EP1689354A2 Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
| 08/16/2006 | EP1689352A2 Combinations for the treatment of proliferative diseases |
| 08/16/2006 | EP1689350A1 Use of osteopontin in dental formulations |
| 08/16/2006 | EP1689348A2 Oligosaccharide compositions and use thereof in the treatment of infection |
| 08/16/2006 | EP1689254A2 Carbohydate and electrolyte replacement composition |
| 08/16/2006 | EP1689249A1 Dietary non-essential amino acid tyrosine regulates the body weight of animals through regulating the animal appetite or food intake |
| 08/16/2006 | EP1689248A1 Companion animal compositions comprising short chain oligofructose |
| 08/16/2006 | EP1689233A2 Bicyclic inhibitors of mek and methods of use thereof |
| 08/16/2006 | EP1689223A2 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
| 08/16/2006 | EP1626729A4 Compositions and methods for symptomatic relief |
| 08/16/2006 | EP1575618B1 Dispersible pharmaceutical compositions |